Meeting
2016 ASCO Annual Meeting
Predictive value of KRAS mutation status in metastatic colorectal cancer (mCRC) patients treated with capecitabine and bevacizumab (CAP-B) maintenance treatment vs observation in the phase III CAIRO3 study.
Authors
Kaitlyn K.H. Goey
Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
Kaitlyn K.H. Goey , Sjoerd G. Elias , Harm van Tinteren , Miangela M. Lacle , Stefan M. Willems , Wendy W.J. de Leng , Eric Strengman , Celien Vreuls , Geert-Jan Creemers , Ankie Van Der Velden , Cornelis J. A. Punt , Miriam Koopman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT00442637
Citation
J Clin Oncol 34, 2016 (suppl; abstr 3525)
DOI
10.1200/JCO.2016.34.15_suppl.3525
Abstract #
3525
Poster Bd #
222
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2021 ASCO Annual Meeting
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2020 Gastrointestinal Cancers Symposium
Analysis of consensus molecular subtypes (CMS) classification in the TRICOLORE trial: A randomized phase III trial of S-1 and irinotecan (IRI) plus bevacizumab (Bmab) versus mFOLFOX6 or CapeOX plus Bmab as first-line treatment for metastatic colorectal cancer (mCRC).
First Author: Satoshi Yuki
Poster
2019 Gastrointestinal Cancers Symposium
KRAS mutation status to predict response in first-line capox and bevacizumab therapy for metastatic colorectal cancer.
First Author: You Yone